Co-Authors
This is a "connection" page, showing publications co-authored by Nivedita Gupta and Gajanan Sapkal.
Connection Strength
2.646
-
Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine. J Travel Med. 2021 10 11; 28(7).
Score: 0.243
-
Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals. J Travel Med. 2021 10 11; 28(7).
Score: 0.243
-
Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. J Travel Med. 2021 Jun 01; 28(4).
Score: 0.237
-
Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG. Indian J Med Res. 2020 May; 151(5):444-449.
Score: 0.220
-
Authors' response. Indian J Med Res. 2020 05; 151(5):496.
Score: 0.220
-
Laboratory preparedness for SARS-CoV-2 testing in India: Harnessing a network of Virus Research & Diagnostic Laboratories. Indian J Med Res. 2020 Feb & Mar; 151(2 & 3):216-225.
Score: 0.216
-
Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis. Indian J Med Res. 2020 Feb & Mar; 151(2 & 3):172-176.
Score: 0.216
-
Comparison of two commercial ELISA kits for detection of rubella specific IgM in suspected congenital rubella syndrome cases and rubella IgG antibodies in a serosurvey of pregnant women. Diagn Microbiol Infect Dis. 2019 Jul; 94(3):243-247.
Score: 0.201
-
First laboratory confirmation on the existence of Zika virus disease in India. J Infect. 2018 03; 76(3):314-317.
Score: 0.184
-
Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med. 2021 10 11; 28(7).
Score: 0.061
-
Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. iScience. 2021 Apr 23; 24(4):102298.
Score: 0.058
-
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021 07; 21(7):950-961.
Score: 0.058
-
Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun. 2021 03 02; 12(1):1386.
Score: 0.058
-
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021 05; 21(5):637-646.
Score: 0.058
-
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. iScience. 2021 Feb 19; 24(2):102054.
Score: 0.058
-
Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection. Indian J Med Res. 2020 May; 151(5):479-482.
Score: 0.055
-
First isolation of SARS-CoV-2 from clinical samples in India. Indian J Med Res. 2020 Feb & Mar; 151(2 & 3):244-250.
Score: 0.054
-
Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran & China, & Italian tourists in India. Indian J Med Res. 2020 Feb & Mar; 151(2 & 3):255-260.
Score: 0.054
-
Burden of dengue infection in India, 2017: a cross-sectional population based serosurvey. Lancet Glob Health. 2019 08; 7(8):e1065-e1073.
Score: 0.052
-
Sero-prevalence of rubella among pregnant women in India, 2017. Vaccine. 2018 12 18; 36(52):7909-7912.
Score: 0.050
-
Sentinel Surveillance for Congenital Rubella Syndrome - India, 2016-2017. MMWR Morb Mortal Wkly Rep. 2018 Sep 14; 67(36):1012-1016.
Score: 0.049